CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Qiagen Marseille SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Qiagen Marseille SA
Za De Courtaboeuf Parc Technopolis
3 Av Du Canada
Phone: +33 160920926p:+33 160920926 LES ULIS, 91940  France Ticker: ALIPSALIPS

This is a Subsidiary, click here for the Parent Company

Business Summary
Qiagen Marseille SAS, formerly known as Qiagen Marseille SA is a France-based company engaged in the development, manufacturing and marketing of molecular diagnostic tests. It offers a range of molecular tests to profile blood cancer and breast and provide guidance in diagnostics. It sells its products to reference centers for cancer therapy, private laboratories and distributors in 50 countries. The Company has more than 80 product references in five continents for the diagnosis, prognosis and monitoring of patients. It operates one wholly owned subsidiary Ipsogen Inc. The Company formed partnerships with a number of institutions and healthcare companies, including Universite Libre de Bruxelles, University of Ohio, Genzyme Genetics and others. In the blood cancer field, Ipsogen is a member of the European LeukemiaNet (ELN) network. It also holds license to biomarker calreticulin (CALR) from the Research Center for Molecular Medicine of the Austrian Academy of Sciences.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201412/31/2014Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer Peer M.Schatz 56 3/17/2015 7/12/2011
Chief Financial Officer RolandSackers 54 3/17/2015 7/12/2011
Chief Operating Officer, Director of Human Resources, Member of the Executive Committee, Director StephaneDebono 3/20/2008 3/20/2008
6 additional Officers and Directors records available in full report.

Business Names
Business Name
ALIPS
Ipsogen SA
IPSOGEN, Inc.

General Information
Number of Employees: 74 (As of 12/31/2014)
Outstanding Shares: 5,445,583 (As of 12/31/2014)
Stock Exchange: EPA
Fax Number: +33 160920925


Copyright © 2022 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, May 4, 2022